(S)-2-Amino-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide, 97%, 250mg

1-Metil-3-octil-imidazolio-, hexafluorofosfato >99%, 25 g, envase de vidrio

Sodium (S)-2-hydroxypentanedioate, 95.0%, 25g

Methyl 5-chlorothiazole-4-carboxylate, 95.0%, 1g

N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide, 95.0%, 1g

Dimethyl 2-(2-nitro-4-(trifluoromethyl)phenyl)malonate, 95.0%, 5g

2,5-Bis(methylsulfonyl)benzene-1,4-diamine, 98%, 200mg

(S)-5-Hydroxypiperidin-2-one, 95.0%, 5g

5-Bromo-2-adamantanone>98.0%(GC)1g

8-Bromo-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, 98%, 250mg

6-Bromo-2,3-dichlorobenzaldehyde, 98%, 1g

Solución estándar multielemento para ICP-MS, 500 ml

N-Ethylpropionamide, 98%, 5g